Summary
TECOS was a large randomized placebo-controlled trial in patients with type 2 diabetes mellitus and cardiovascular disease, conducted to demonstrate the noninferiority of sitagliptin as compared with placebo in the risk of cardiovascular events. A prespecified secondary analysis found no impact of sitagliptin on heart failure hospitalization or related events.
- cardiovascular outcomes
- heart failure
- hospitalization
- randomized controlled trial
- type 2 diabetes mellitus
- sitagliptin
- © 2015 SAGE Publications